Clinical trials: sponsored by Amgen
Rectal Cancer, Colon Cancer
Safety of AMG 706 Plus Panitumumab Plus Chemotherapy in the Treatment of Subjects With Metastatic Colorectal Cancer
The purpose of this study is to characterize the safety and tolerability of AMG 706 plus panitumumab when administered with either FOLFIRI or FOLFOX4 chemotherapy regimens. This is a Phase 1b clinical study.
- Trial name
- NCT00101894
- Testing
- FOLFOX-4, AMG 706, Panitumumab (Part 1a only)
- Volunteers
- 119 people
- Sponsor
- Amgen
Healthy Volunteers
A Phase 1 Multiple Dose Study to Compare the Effects of AMG 223 and Sevelamer HCL (Renagel®)
The purpose of this study is to determine if subjects on 2g AMG 223 will achieve 60% or greater reduction in urinary phosphorus from baseline compared to subjects on 2g Renagel®.
- Trial name
- NCT00756860
- Testing
- AMG 223, Renagel® (sevelamer hydrochloride)
- Volunteers
- 66 people, healthy volunteers welcome
- Sponsor
- Amgen Research (Munich) GmbH
Liver Metastases, Colorectal Cancer
Study of Adecatumumab Relative to FOLFOX After R0 Resection of Colorectal Liver Metastases
The purpose of this study is to determine the effect of adecatumumab alone or following FOLFOX in patients with R0 resected liver metastases from CRC (colorectal carcinoma) and to compare the effect to FOLFOX alone.
- Trial name
- MT201-204 (NCT00866944)
- Testing
- Adecatumumab, Adecatumumab and FOLFOX, FOLFOX 4
- Where
- 16 sites in France, Germany
- Volunteers
- 35 people
- Sponsor
- Amgen Research (Munich) GmbH
Advanced Solid Tumors
Single Dose Study of [14C]-Labelled AMG 706 in Patients With Advanced Solid Tumors
In order for a tumour to grow and spread to other parts of the body, it needs to have a blood supply. Certain proteins in the body, called cytokines or growth factors, have been shown to cause the growth of new blood vessels that…
- Trial name
- NCT01386866
- Testing
- AMG 706
- Volunteers
- 4 people
- Sponsor
- Amgen
Postmenopausal Osteoporosis
Study of Transitioning From Alendronate to Denosumab
The study will evaluate the efficacy and safety of transitioning postmenopausal women on current alendronate therapy to denosumab.
- Trial name
- NCT00377819
- Testing
- alendronate, Denosumab (AMG 162)
- Volunteers
- 504 people
- Sponsor
- Amgen
Chemotherapy-Induced Thrombocytopenia, Hodgkin's Lymphoma
A Dose and Schedule Finding Trial With AMG 531 for Chemotherapy Induced Thrombocytopenia (CIT) in Adults With Lymphoma
The purpose of this study is to identify a well-tolerated, effective dose and schedule of AMG 531 for the treatment of Chemotherapy Induced Thrombocytopenia (CIT) in subjects with lymphoma receiving multi-cycle chemotherapy.
- Conditions
- Chemotherapy-Induced Thrombocytopenia, Hodgkin's Lymphoma, Non-Hodgkin's Lymphoma, Cancer
- Trial name
- NCT00283439
- Testing
- AMG 531
- Volunteers
- 39 people
- Sponsor
- Amgen
Rheumatoid Arthritis
Rheumatoid Arthritis (DMARD) Intervention and UtilizationStudy
The Rheumatoid Arthritis DMARD Intervention and Utilization Study (RADIUS 1) is designed to systematically collect and document use patterns, effectiveness, and safety of DMARD treatments currently used in the management of…
- Trial name
- NCT00116714
- Testing
- DMARD
- Volunteers
- 4,968 people
- Sponsor
- Amgen
Rheumatoid Arthritis
Rheumatoid Arthritis DMARD Intervention and UtilizationStudy
To systematically collect and document use patterns, effectiveness and safety of DMARD treatments currently used in the management of rheumatoid arthritis.
- Trial name
- NCT00116727
- Testing
- ENBREL®
- Volunteers
- 5,103 people
- Sponsor
- Amgen
Anemia, Cardiovascular Disease
An Exploratory Sub-study for the RED-HF™ (Reduction of Events With Darbepoetin Alfa in Heart Failure) Trial
The purpose of Study 20060172 was to measure echocardiographic parameters and biomarkers in a subgroup of study subjects enrolled in Study 20050222 (the RED-HF Trial).
- Conditions
- Anemia, Cardiovascular Disease, Congestive Heart Failure, Heart Failure
- Trial name
- NCT00534456
- Testing
- Darbepoetin alfa
- Volunteers
- 12 people
- Sponsor
- Amgen
End Stage Renal Disease
A Research Study for Patients With End-Stage Renal Disease (ESRD)
The purpose of this study is to evaluate the ability of a treatment strategy, that includes cinacalcet for the management of secondary hyperparathyroidism, to control parathyroid hormone (PTH) compared with the standard of care.
- Trial name
- NCT00110890
- Testing
- cinacalcet, Standard of care
- Volunteers
- 552 people
- Sponsor
- Amgen
Bone Metastases in Men With Hormone-Refractory Prostate Cancer, Bone Metastases in Subjects With Advanced Breast Cancer
Study of AMG 162 in Subjects With Advanced Cancer Currently Being Treated With Intravenous (IV) Bisphosphonates
The purpose of this trial is to determine the effectiveness of AMG 162 in reducing urinary N-telopeptide in advanced cancer subjects with bone metastases.
- Conditions
- Bone Metastases in Men With Hormone-Refractory Prostate Cancer, Bone Metastases in Subjects With Advanced Breast Cancer, Bone Metastases in Subjects With Advanced Cancer or Multiple Myeloma
- Trial name
- NCT00104650
- Testing
- AMG 162 180 mg (SC) q 12 weeks, IV Bisphosphonate q 4 weeks, AMG 162- 180 mg q 4 weeks
- Volunteers
- 111 people
- Sponsor
- Amgen
Myelodysplastic Syndromes, Thrombocytopenia
A Safety and Efficacy Study to Evaluate AMG 531 Treatment in Subject With Myelodysplastic Syndrome Receiving Revlimid
This is a dose and schedule finding study of AMG 531 designed to assess the activity of AMG 531 to reduce the rate of clinically significant bleeding and blood transfusions in subjects with myelodysplastic syndrome (MDS)…
- Trial name
- NCT00418665
- Testing
- AMG 531
- Volunteers
- 39 people
- Sponsor
- Amgen
Osteoporosis, Osteopenia
A Randomized, Double-Blind Study to Compare the Efficacy of Treatment With Denosumab Versus Alendronate Sodium in Postmenopausal Women With Low Bone Mineral Density.
The purpose of this study is to determine whether in postmenopausal women with low bone mineral density, the mean percent change in total hip BMD in subjects receiving denosumab is not less than that observed in subjects…
- Trial name
- NCT00330460
- Testing
- Alendronate, Denosumab
- Volunteers
- 1,189 people
- Sponsor
- Amgen
Rheumatoid Arthritis
Study of Enbrel in Rheumatoid Arthritis (RA) Subjects With Comorbid Disorders
The objective of this study was to evaluate the safety of Enbrel (etanercept) in rheumatoid arthritis (RA) subjects with greater than or equal to 1 documented comorbid disease (diabetes mellitus; chronic pulmonary disease…
- Trial name
- NCT00132418
- Testing
- Enbrel
- Volunteers
- 564 people
- Sponsor
- Amgen
Kidney Transplantation
Study To Evaluate the Status of Subjects That Discontinued Participation in a Qualifying Amgen Sponsored AMG 073 Study Due to Kidney Transplantation
The purpose of this study is to collect local laboratory data on immunoreactive parathyroid hormone (iPTH), calcium and phosphorus levels and estimated glomerular filtration rate (GFR) at approximately 1 week, 1 month, 3 months…
- Trial name
- NCT00110656
- Testing
- Observations
- Volunteers
- 38 people
- Sponsor
- Amgen
Solid Tumors
Effect of Different Doses of AMG 706 on the Gallbladder in Advanced Solid Tumors
The study involves the use of three different dosing regimens of AMG 706 in patients with advanced solid tumors to see how the drug affects the gallbladder size and function.
- Trial name
- NCT00448786
- Testing
- AMG 706
- Volunteers
- 49 people
- Sponsor
- Amgen
Chronic Kidney Disease
Extension From Weekly to Once Every Other Week Darbepoetin Alfa Administration in Subjects With Chronic Kidney Disease Receiving Dialysis
The purpose of this study is to assess the proportion of subjects sucessfully achieving a mean Hemoglobin greater than or equal to 11 g/dL during the evaluation period following extension from Weekly (QW) to Once Every Other Week…
- Trial name
- NCT00436995
- Testing
- Darbepoetin Alfa
- Volunteers
- 114 people
- Sponsor
- Amgen
Colorectal Cancer
Evaluating ABX-EGF Extended Therapy in Subjects With MetastaticColorectal Cancer
The purpose of this study is to examine the safety of ABX-EGF administered as monotherapy in subjects with metastatic colorectal cancer who were previously randomized to best supportive care (BSC) in protocol 20020408 and…
- Trial name
- NCT00113776
- Testing
- ABX-EGF
- Sponsor
- Amgen
Rheumatoid Arthritis
A Rheumatoid Arthritis (RA) Study Treating Signs and Symptoms of RA in People With RA & Receiving Methotrexate
This clinical study is investigating AMG 719, an investigational drug, for the treatment of patients who have Rheumatoid Arthritis and who are taking Methotrexate.
- Trial name
- NCT00038298
- Testing
- AMG 719, AGM 719
- Volunteers
- 53 people
- Sponsor
- Amgen
Kidney Disease
Study to Evaluate Effectiveness of Aranesp®
The purpose of this study was to evaluate subject preference for Aranesp® administered once monthly (i.e., every 4 weeks (Q4W)) or Procrit® administered once weekly (QW).
- Trial name
- NCT00117130
- Testing
- Aranesp®
- Sponsor
- Amgen
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.